Posted on September 30, 20259/30/25
Strategic PICO Planning: Navigating Oncology Markets with NAVLIN by EVERSANA
Posted on September 30, 20259/30/25
Strategic PICO Planning: Enhancing Early-Phase Development for Market Access
Posted on September 11, 20259/11/25
The Most-Favored-Nation Model: Global Benchmark or Global Risk?
Posted on September 10, 20259/10/25
The Evolution of the 340B Rebate Model: Maintaining Patient Access while Minimizing Duplicate Discounts
Posted on September 10, 20259/10/25
2026 CMS Proposed Rule: BFSF Changes and Potential Risks for Pharma Manufacturers
Posted on September 10, 20259/10/25
Navigating OBBBA: Why a Strong GP Team is Essential for Pharma Compliance
Posted on August 25, 20258/25/25
Evaluation of HTA Frameworks for In Vivo Diagnostics: Assessing Methodological Gaps and Implications for Market Access
Posted on August 22, 20258/22/25
Navigating MFN: Alan Crowther on What Pharma Brands Must Know Now
Posted on July 22, 20257/22/25
Case Study: Transforming Market Access with NAVLIN Insights KPI
Posted on July 15, 20257/15/25